ERBB2 and colorectal carcinoma: Recently, HER2 gained a lot of interest in CRC, as two recent clinical trials, MyPathway (trastuzumab and pertuzumab) and HERACLES (trastuzumab and lapatinib), demonstrated promising clinical benefit for dual HER2 blockade in patients with HER2-amplified mCRC (reviewed in [89,90]).